Search Results
Your search for The,The matches 34168 pages
Showing 101 - 150FDA Approves Ensartinib for ALK- Positive Locally Advanced or Metastatic NSCLC
On December 18, 2024, the U.S. Food and Drug Administration (FDA) approved the anaplastic lymphoma kinase (ALK) inhibitor ensartinib (Ensacove) for adults with ALK-positive locally advanced or metastatic non–small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor. For full...
CAR T-Cell Therapy for Relapsed/Refractory Mantle Cell Lymphoma: ZUMA-2
Long-term follow-up of patients in ZUMA-2 cohorts 1 and 2 showed that 39% of patients with relapsed/refractory mantle cell lymphoma were alive after 5 years; patients in these cohorts received brexucabtagene autoleucel, the only chimeric antigen receptor (CAR) T-cell therapy to have 5-year...
Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
A primary analysis of ZUMA-2, reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, demonstrated durable responses to brexucabtagene autoleucel in patients with Bruton’s tyrosine kinase (BTK) inhibitor–naive mantle cell lymphoma. The findings from cohort 3 of...
Unresectable Locally Advanced KRAS-Mutant NSCLC
This is Part 3 of Clinical Perspectives on KRAS-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Gregory Riely, Rebecca Heist, and Joshua Sabari discuss the management of a patient with unresectable locally...
Second-Line Treatment of KRAS-Mutant Metastatic NSCLC
This is Part 2 of Clinical Perspectives on KRAS-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Gregory Riely, Rebecca Heist, and Joshua Sabari discuss the second-line treatment of a patient with KRAS-mutant...
First-Line Treatment of KRAS-Mutant NSCLC
This is Part 1 of Clinical Perspectives on KRAS-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Gregory Riely, Rebecca Heist, and Joshua Sabari discuss the first-line treatment of a patient with KRAS-mutant...
Researchers May Have Uncovered Protein That Helps Cancer Cells Dodge CAR T-Cell Therapy
Researchers may have discovered a factor contributing to cancer cell evasion of chimeric antigen receptor (CAR) T-cell therapy, according to a recent study published by Chen et al in Cell. The findings could lead to more personalized therapies that improve survival among patients with cancer....
UICC, ICCP: Landmark Review of National Cancer Strategies Illuminates Progress, Persistent Challenges
The Union for International Cancer Control (UICC) has examined the National Cancer Control Plans and reported their findings in a new comprehensive global review published by Romero et al in The Lancet Oncology. The findings will be presented at the Cancer Planners Forum in May 2025 in Geneva,...
Larotrectinib in Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors
In a Children’s Oncology Group study (ADVL1823) reported in Journal of Clinical Oncology, Laetsch et al found that larotrectinib was highly active in patients with newly diagnosed infantile fibrosarcoma and other pediatric NTRK fusion–positive solid tumors. Study Details The U.S. multicenter trial...
Novel Formulation Used in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting
In a Chinese phase III trial (PROFIT) reported in Journal of Clinical Oncology, Zhou et al found that mixed-formulation fosrolapitant/palonosetron (HR20013) plus dexamethasone was noninferior to individually dosed fosrolapitant plus palonosetron plus dexamethasone in preventing chemotherapy-induced ...
Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally Advanced NSCLC
In a phase II trial reported in The Lancet Oncology, Heinzerling et al found evidence of efficacy of primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemotherapy and consolidative immunotherapy in patients with locally advanced non–small cell lung cancer...
CBD May Not Reduce Scan-Related Anxiety in Patients With Advanced Breast Cancer
Cannabidiol (CBD) may not significantly change scan-related anxiety compared with placebo in patients with advanced breast cancer but may result in lower overall anxiety levels, according to a recent study published by Nayak et al in JAMA Network Open. Background Anxiety is common among adult...
Generic Platinum Chemotherapy Shortages May Not Have Increased Mortality
During a shortage of the generic platinum chemotherapy drugs cisplatin and carboplatin that began in early 2023, investigators found no difference in mortality rates among patients with advanced cancer compared with the previous year, according to a recent study published by Reibel et al in the...
Anthracyclines Plus Taxane-Based Chemotherapy for Certain Patients at High Risk for Breast Cancer Recurrence
Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2-negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline plus taxane-based chemotherapy regimens compared with those...
Managing Comorbidities in Oncology: Practical Strategies for Optimized Patient Care
Cancer care is increasingly complicated by the presence of comorbidities, which affect nearly two-thirds of patients at the time of diagnosis and can influence treatment decisions, participation in clinical trials, and overall outcomes. During 2024 JADPRO Live, M. Edie Brucker, DNP, MPH, ARNP,...
HIPEC in Platinum-Sensitive Recurrent Ovarian Cancer
In an Italian phase III trial (HORSE; MITO-18) reported in Journal of Clinical Oncology, Fagotti et al found that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to secondary cytoreductive surgery without neoadjuvant chemotherapy did not improve progression-free survival vs no...
Balancing Pain Management and Addiction Risks in Oncology
Managing cancer pain in patients with substance use disorder presents a unique challenge for oncologists, requiring a balance between effective symptom management and mitigation of the risks of substance misuse. During the 2024 JADPRO Live, Antonia Corrigan, MSN, ANP-C, ACHPN, emphasized the...
Effectiveness of Multimodal Machine-Learning Model in Predicting Response to Treatment in Breast Cancer Subtype
A machine-learning model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data alone in predicting which patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer would have better outcomes from adding CDK4/6...
Improving Hepatocellular Carcinoma Outcomes Through Enhanced Immunotherapy
A novel strategy may increase the activity of dendritic cells and improve immunotherapy outcomes in patients with hepatocellular carcinoma, according to a recent study published by Morita et al in Cancer Immunology Research. Background Hepatic cancer is a disease with a poor prognosis. Despite...
Low Omega-6/High Omega-3 Diet and Fish Oil Supplementation May Help Slow Prostate Cancer Growth
Researchers have found that dietary changes may help reduce cancer cell growth in patients with prostate cancer undergoing active surveillance, according to a recent study published by Aronson et al in the Journal of Clinical Oncology. The findings demonstrated that a diet low in omega-6 and high...
Learning From the ZEST Trial in Using ctDNA to Predict Breast Cancer Recurrence
The phase III ZEST clinical trial, designed to evaluate the PARP inhibitor niraparib for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA, according to results presented at the 2024 San Antonio Breast...
Cosibelimab-ipdl Approved by FDA for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
The U.S. Food and Drug Administration (FDA) approved cosibelimab-ipdl (Unloxcyt), a PD-L1–blocking antibody, for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation therapy. The approval was granted on December 13,...
Negative Colonoscopy Screening Results and Risk for Colorectal Cancer and Mortality
In a study reported in JAMA Oncology, Knudsen et al found evidence supporting the consideration of extending the rescreening intervals after a negative colonoscopy screening result beyond the currently recommended 10 years, particularly among individuals with a low-risk profile. Study Details The...
Cara Norelli, MS, AGNP-C, on Managing Dermatologic Side Effects in Patients With Cancer
Cara Norelli, MS, AGNP-C, of Memorial Sloan Kettering Cancer Center, discusses her presentation on dermatologic toxicities seen in patients with cancer from the JADPRO Live conference recently held in Grapevine, Texas. Ms. Norelli covers the importance of knowing the distinguishing characteristics...
My Cancer Diagnosis and Renewed Commitment to Fight for Patients
Over 40 years ago, I lost my dear sister, Gale, to cancer. She left behind a beautiful 4-year-old daughter and a grieving family. Driven by this profound loss, I was determined to ensure that no other family would face that same heartbreak. That resoluteness led to the founding of Friends of...
Andrew Tutt, MB ChB, PhD, FMedSci, on OlympiA: High-Risk BRCA-Positive Breast Cancer
Andrew Tutt, MB ChB, PhD, FMedSci, Director of The Breast Cancer Now Toby Robins Research Centre and the Institute of Cancer Research (ICR) and Guy’s Hospital King’s College, London, discusses longer-term follow-up of OlympiA, a phase III, multicenter, randomized, placebo-controlled trial of...
Geriatric Surgery Verification Program May Improve Outcomes in Older Patients With Cancer in Community Hospitals
Implementing the American College of Surgeons (ACS) Geriatric Surgery Verification program may help to improve postoperative outcomes and preserve independence in older patients with cancer undergoing major abdominal procedures, according to a recent study published by Jimenez et al in the Journal...
Nan Chen, MD, on Impact of Anthracyclines in High Genomic Risk Node-Negative HR-Positive/HER2-Negative Breast Cancer
Nan Chen, MD, of the University of Chicago Medicine, Chicago, discusses the impact of anthracyclines in high genomic risk node-negative HR-positive/HER2-negative breast cancer (Abstract GS3-03).
Trastuzumab Deruxtecan vs Chemotherapy in Advanced Breast Cancer
Researchers have examined whether the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) may improve progression-free survival in patients with advanced breast cancer who have undergone prior hormone-based therapies, according to recent findings presented by Bardia et al at the 2024...
Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients With ‘Good-Risk’ DCIS Who Forgo Radiation
For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according to results presented at the 2024 San Antonio Breast Cancer Symposium...
Most Patients With Intermediate-Risk Breast Cancer May Safely Avoid Chest Wall Irradiation After Mastectomy
Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they underwent chest wall irradiation after mastectomy, according to results from the BIG 2-04 MRC SUPREMO clinical trial, presented by Ian Kunkler, MA, MB BChir, of the University of...
Intermittent or Continuous Panitumumab Plus FOLFIRI in First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer
In an Italian phase II trial (IMPROVE) reported in the Journal of Clinical Oncology, Avallone et al found that intermittent panitumumab and FOLFIRI (fluorouracil, leucovorin, and irinotecan) was associated with promising progression-free survival as first-line treatment in patients with RAS/BRAF...
Kathryn Newlin, RN, MSN, ANP-BC, on Updates in HR-Positive, HER2-Negative Metastatic Breast Cancer
Kathryn Newlin, RN, MSN, ANP-BC, of Washington University in St. Louis, discusses her presentation on HR+ HER2- metastatic breast cancer from the JADPRO Live conference recently held in Grapevine, Texas. Kathryn covers factors involved in treatment selection for this patient population, including...
Adrienne Waks, MD, on MARGOT/TBCRC052: Phase II Trial in HER2-Positive Breast Cancer
Adrienne Waks, MD, of Dana-Farber Cancer Institute, Boston, discusses the randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab vs paclitaxel/trastuzumab/pertuzumab in patients with stage II-III HER2-positive breast cancer. This trial is being done to determine how well ...
Aditya Bardia, MD, on Destiny-Breast06: An Additional Analysis
Aditya Bardia, MD, of UCLA David Geffen School of Medicine, Los Angeles, presents the additional analysis of the efficacy and safety of trastuzumab deruxtecan vs physician’s choice of chemotherapy by pace of disease progression on prior endocrine-based therapy from DESTINY-Breast06 (Abstract...
Mafalda Oliveira, MD, PhD, on Primary Results of SOLTI VALENTINE
Mafalda Oliveira, MD, PhD, of Vall d’Hebron Institute of Oncology, Spain, presented the primary results of SOLTI VALENTINE, a neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor–positive/HER2-negative early breast cancer (Abstract...
Sibylle Loibl, MD, PhD, on Primary Results of the Randomized, Phase III PADMA Study in HER2-Negative/HR-Positive Metastatic Breast Cancer
Sibylle Loibl, MD, PhD, of the German Breast Group, Neu-Isenburg, Germany, presented primary results of the randomized phase III PADMA trial comparing first-line endocrine therapy plus palbociclib vs standard mono-chemotherapy in women with high-risk HER2-negative/HR-positive metastatic breast...
Autologous Stem Cell Transplantation May Not Improve Survival in Patients With MCL and Undetectable Minimal Residual Disease
Researchers have revealed that high-dose chemotherapy followed by autologous stem cell transplantation may not benefit patients with mantle cell lymphoma (MCL) who are in remission following initial treatment, according to new findings presented by Fenske et al at the 2024 American Society of...
Blinatumomab in Combination With Chemotherapy May Improve Survival in Pediatric Patients Newly Diagnosed With B-Cell Precursor ALL
The addition of blinatumomab to chemotherapy may improve disease-free survival in pediatric patients newly diagnosed with National Cancer Institute (NCI) standard-risk B-cell acute lymphoblastic leukemia (ALL) at average or high risk of relapse, according to new findings presented by Rau et al at...
Quality of Life Similar Among Patients With Low-Risk DCIS Whether They Received Active Monitoring or Surgery
Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring and those who received upfront treatment reported comparable physical, emotional, and psychological outcomes, according to results from the COMET trial presented at the 2024 San Antonio Breast Cancer Symposium...
Active Monitoring May Be a Viable Option for Some Patients With Low-Risk DCIS
Among patients with hormone receptor–positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar 2-year invasive ipsilateral breast cancer recurrence rates as those who underwent guideline-concordant treatment, according to results from the...
Bicistronic CAR T-Cell Therapy Achieved Durable Remissions in Children With Relapsed/Refractory B-Cell ALL
A follow-up study investigating the coadministration of CD19- and CD22-targeted chimeric antigen receptor (CAR) T-cell therapy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) found the therapy is safe and effective and achieved durable remissions in these patients, ...
Nivolumab/Ipilimumab vs Chemotherapy With or Without Targeted Agents in MSI-H or dMMR Metastatic Colorectal Cancer
As reported in The New England Journal of Medicine by Andre et al, interim analysis of the phase III CheckMate 8HW trial has shown that nivolumab plus ipilimumab prolonged progression-free survival vs chemotherapy with or without targeted agents in patients with microsatellite instability–high...
Justin Arnall, PharmD, BCOP, FCCP, on Complicating “Factors”: When Malignancy and Non-Malignant Hematology Collide
Justin Arnall, PharmD, BCOP, FCCP, of Atrium Health Specialty Pharmacy Service in Charlotte, North Carolina, discusses his JADPRO Live presentation on critical considerations when planning for cancer-related procedures in patients with hereditary/congenital as well as acquired bleeding disorders.
Tiffany Traina, MD, FASCO, on Advances in the Treatment of HR-Positive Breast Cancer
Tiffany Traina, MD, FASCO, is Vice Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center, where she has been a medical oncologist on the Breast Medicine Service since 2006. Dr. Traina is also the Section Head of the Triple Negative Breast Cancer Clinical Research Program. In ...
BRCA-Mutation Carriers With Prior Diagnosis of Early-Onset Breast Cancer May Benefit From Risk-Reducing Surgery
Patients with germline BRCA gene mutations and a history of early-onset breast cancer who underwent a bilateral risk-reducing mastectomy and/or a risk-reducing salpingo-oophorectomy had lower rates of recurrence, secondary breast and/or ovarian malignancies, and death than those who did not...
Fiber-Rich Diet May Help Prevent Complications After Stem Cell Transplant
Consuming a high-fiber diet after undergoing stem cell transplantation may help to reduce the risk of graft-vs-host disease (GVHD) by cultivating a healthy gut microbiome, according to research presented by Paredes et al at the 2024 American Society of Hematology (ASH) Annual Meeting &...
Pirtobrutinib May Improve Survival Outcomes in Pretreated Patients With CLL or SLL
Researchers have found that the noncovalent Bruton's tyrosine kinase inhibitor (BTK) pirtobrutinib may offer superior progression-free survival in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to recent findings presented by Sharman et al at the 2024...
Combination of Two Oral Agents May Improve Progression-Free Survival in Patients With Previously Untreated CLL
A combination of the oral drugs acalabrutinib and venetoclax may be more effective at improving progression-free survival and minimizing serious adverse events in patients with previously untreated chronic lymphocytic leukemia (CLL) compared with one of two standard multidrug treatment regimens,...
High-Fiber Diet May Slow Disease Progression to Multiple Myeloma
Recent data suggest that a plant-based diet rich in fiber may help to improve the outlook for people with precursor conditions that can lead to multiple myeloma. The research, which involved a 12-week controlled diet with additional health coaching for 20 patients as well as experiments in mice, is ...
